DESC:DESCRIPTION:
Field of the invention:
[0001] The present disclosure generally relates to the technical field of biotechnology, and in specific relates to, a composition of a transdermal patch that utilizes a combination of natural plant extracts and modern drug delivery technology to enhance therapeutic efficacy and ensure prolonged drug release for Verrucae vulgaris and acne treatment.
Background of the invention:
[0002] Acne is a long-lasting inflammatory skin condition that occurs through blocked and inflamed sebaceous glands and hair follicles. A number of substances accumulate in the hair and sebaceous gland during puberty; bacteria and oil attach to the hair and sebaceous gland, and the resultant redness and swelling of the skin are caused by the hormones in the body that stimulate hair growth and encourage the sebaceous gland to secrete more oil. Acne not only damages the skin and face but also causes harm to the surrounding tissues, worsens inflammation, leaves marks on the skin if the acne is squeezed improperly, and spreads bacteria into the bloodstream.

[0003] Warts on the hands are benign (non-cancerous) skin growths that occur on most parts of the body, including the face, foot, and genitalia. The human papillomavirus, or HPV, is the cause of them all and enters the skin through microscopic wounds and abrasions. Warts can spread through skin-to-skin contact, especially in people with compromised immune systems. Although treating hand warts at home can be difficult, there are a few reliable remedies. You should seek medical attention if they are ineffective for you.

[0004] At present, there are multiple methods for removing acne, which include laser acne removal, acne removal by using traditional medicines containing natural plants such as aloe and tea trees, and acne removal by using pharmaceutical medicines such as salicylic acid and prednisone, but the existing acne removal methods have certain limitations.

[0005] The treatment effect of the laser acne removal method is too strong, and the laser acne removal method is only used for removing acne by a physical method and cannot treat acne from roots. Although acne removal through traditional medicines is safe, the removal time is long, and acne marks are difficult to fade after acne removal. Furthermore, the pharmaceutical medicines for acne removal have strong side effects and involve high costs.

[0006] By addressing all the above-mentioned problems, there is a need for a transdermal patch that utilizes plant extracts for Verrucae vulgaris and acne treatment. There is also a need for a transdermal patch that eliminates the need for frequent application, as the patch provides continuous medication delivery over an extended period. There is also a need for a transdermal patch that reduces the potential side effects associated with oral medications. There is also a need for a transdermal patch that provides a safe, localized, and holistic treatment approach. There is a need for a transdermal patch that reduces the chances of inconsistent treatment and enhances patient convenience and adherence. There is a need for a transdermal patch that offers several unique benefits compared to other transdermal patches that include natural ingredients, synergistic effects, reduced side effects, targeted action, enhanced absorption, potential synergy with skin, and a holistic approach.
Objectives of the invention:
[0007] The primary objective of the invention is to provide a transdermal patch that utilizes a combination of natural plant extracts and modern drug delivery technology to enhance therapeutic efficacy and ensure prolonged drug release for Verrucae vulgaris and acne treatment.

[0008] Another objective of the invention is to provide a transdermal patch that eliminates the need for frequent application of medication, as the patch provides continuous delivery of medication for an extended period.

[0009] The other objective of the invention is to provide a transdermal patch that reduces the systemic side effects associated with oral medications.

[0010] The other objective of the invention is to provide a transdermal patch that is safe and cost-effective.

[0011] The other objective of the invention is to provide a transdermal patch that enhances bioavailability.

[0012] Yet another objective of the invention is to provide a transdermal patch that enhances patient convenience and adherence.

[0013] Further objective of the invention is to provide a transdermal patch with synergistic effects that result in targeted treatment for users.
Summary of the invention:
[0014] The present disclosure proposes a composition of a transdermal patch for Verrucae vulgaris and acne treatment. The following presents a simplified summary in order to provide a basic understanding of some aspects of the claimed subject matter. This summary is not an extensive overview. It is not intended to identify key/critical elements or to delineate the scope of the claimed subject matter. Its sole purpose is to present some concepts in a simplified form as a prelude to the more detailed description that is presented later.

[0015] In order to overcome the above deficiencies of the prior art, the present disclosure is to solve the technical problem to provide a composition of a transdermal patch that utilizes a combination of natural plant extracts and modern drug delivery technology to enhance therapeutic efficacy and ensure prolonged drug release for Verrucae vulgaris and acne treatment.

[0016] According to an aspect, the invention provides a composition of a transdermal patch for Verrucae vulgaris and acne treatment. The composition comprises 0.5 to 1 weight percent of a drug, T.occidentalis salicylic acid (TOSA), 1 to 2 weight percent of a bioactive polymer, 0.1 to 0.6 weight percent of a synthetic polymer, 0.1 to 0.6 weight percent of a plasticizer, 40 to 46 weight percent of a solvent, 0.1 to 0.6 weight percent of a penetration enhancer, 40 to 46 weight percent of distilled water, and 3 to 5 weight percent of glycerol. In one embodiment herein, the transdermal patch composition provides a safe and effective solution for the treatment of skin conditions such as verrucae vulgaris and acne.

[0017] In one embodiment herein, the drug T.occidentalis salicylic acid (TOSA) comprises carbohydrates, alkaloids, tannins, saponins, flavonoids, oils, lipids, and glycosides. In one embodiment herein, the bioactive polymer is a hydroxypropyl methylcellulose (HPMC) polymer. In one embodiment herein, the synthetic polymer is a polyvinyl alcohol (PVA) polymer.

[0018] In one embodiment herein, the plasticizer is dibutylphthalate. In one embodiment herein, the solvent is methanol. In one embodiment herein, the penetration enhancer is dimethyl sulfoxide (DMSO). In one embodiment, the transdermal patch is configured to release the drug T.occidentalis salicylic acid (TOSA) over a predetermined time period of at least 12 hr.

[0019] In one embodiment herein, the transdermal patch comprises a backing layer and a protective layer. The backing layer is impermeable to the drug T.occidentalis salicylic acid (TOSA). The protective layer is peelable and aids a user in applying the transdermal patch to the skin.

[0020] According to another aspect, the invention provides a method for manufacturing the transdermal patch for Verrucae vulgaris and acne treatment. At one step, the bioactive polymer and the synthetic polymer are weighed and dissolved in a solvent mixture, which includes at least 10 mL of distilled water and 10 mL of methanol, thereby obtaining a polymer solution.

[0021] At another step, the polymer solution is mixed using a magnetic stirrer at a temperature of at least 45 °C, and the drug T.occidentalis salicylic acid (TOSA) is added to the polymer solution, and mixed thoroughly to obtain a uniform polymer-drug mixture.

[0022] At another step, the plasticizer and the penetration enhancer are mixed into the polymer-drug mixture and thoroughly mixed to obtain a mixture. At another step, one drop of a coloring agent (safranin indicator) is added to the mixture to obtain a final casting solution, and a petri dish is lubricated with 1 mL of glycerol.

[0023] At another step, the final casting solution is poured into the lubricated petri dish and allowed to spread evenly over an area of approximately 44.15 cm². At another step, the petri dish is covered with an inverted funnel, and the solution is allowed to dry at room temperature for a time period of at least 96 hr to form the transdermal patch.

[0024] Further, at other step, the dried film is peeled off and cut into a plurality of square patches measuring 1 cm² each and placed in a desiccator for at least two days for further drying, and the plurality of dried patches are wrapped in aluminum foil and stored in self-sealing covers for usage.

[0025] Further, objects and advantages of the present invention will be apparent from a study of the following portion of the specification, the claims, and the attached drawings.
Detailed description of drawings:
[0026] The accompanying drawings, which are incorporated in and constitute a part of the specification, illustrate an embodiment of the invention, and, together with the description, explain the principles of the invention.

[0027] FIG. 1 illustrates a block diagram of a composition of a transdermal patch for Verrucae vulgaris and acne treatment, in accordance to an exemplary embodiment of the invention.

[0028] FIG. 2 illustrates a flowchart of a method for manufacturing the transdermal patch for Verrucae vulgaris and acne treatment, in accordance to an exemplary embodiment of the invention.
Detailed invention disclosure:
[0029] Various embodiments of the present invention will be described in reference to the accompanying drawings. Wherever possible, same or similar reference numerals are used in the drawings and the description to refer to the same or like parts or steps.

[0030] The present disclosure has been made with a view towards solving the problem with the prior art described above, and it is an object of the present invention to provide a composition of a transdermal patch that utilizes a combination of natural plant extracts and modern drug delivery technology to enhance therapeutic efficacy and ensure prolonged drug release for Verrucae vulgaris and acne treatment.

[0031] According to one exemplary embodiment of the invention, FIG. 1 refers to a block diagram of a composition of a transdermal patch 100 for Verrucae vulgaris and acne treatment. The proposed transdermal patch 100 eliminates the need for frequent application of medication as it provides continuous delivery of medication for an extended period. The transdermal patch 100 reduces the systemic side effects associated with oral medications. The transdermal patch 100 is safe and cost-effective. The transdermal patch 100 enhances patient convenience and adherence. The transdermal patch 100 enhances synergistic effects and targeted action.

[0032] The composition comprises 0.5 to 1 weight percent of a drug T.occidentalis salicylic acid TOSA 102, 1 to 2 weight percent of a bioactive polymer 104, 0.1 to 0.6 weight percent of a synthetic polymer 106, 0.1 to 0.6 weight percent of a plasticizer 108, 40 to 46 weight percent of a solvent 110, 0.1 to 0.6 weight percent of a penetration enhancer 112, 40 to 46 weight percent of distilled water 114, and 3 to 5 weight percent of glycerol 116. In one embodiment herein, the transdermal patch composition provides a safe and effective solution for the treatment of skin conditions such as verrucae vulgaris and acne.

[0033] In one embodiment herein, the composition comprises 150 mg of the drug T.occidentalis salicylic acid TOSA 102, 400 mg of the bioactive polymer 104, 100 mg of the synthetic polymer 106, 0.1 mL of the plasticizer 108, 10 mL of the solvent 110, 0.1 mL of the penetration enhancer 112, 10 mL of the distilled water 114, and 1 mL of the glycerol 116.

[0034] In one embodiment herein, the drug T.occidentalis salicylic acid TOSA 102 comprises carbohydrates, alkaloids, tannins, saponins, flavonoids, oils, lipids, and glycosides. In one embodiment herein, the bioactive polymer is hydroxypropyl methylcellulose (HPMC) 104. In one embodiment herein, the synthetic polymer is polyvinyl alcohol (PVA) 106.

[0035] In one embodiment herein, the plasticizer 108 is dibutylphthalate. In one embodiment herein, the solvent is methanol. In one embodiment herein, the penetration enhancer is dimethyl sulfoxide (DMSO) 112. In one embodiment, the transdermal patch is configured to release the drug T.occidentalis salicylic acid TOSA 102 over a predetermined time period of at least 12 hours.

[0036] In one embodiment herein, the transdermal patch comprises a backing layer and a protective layer. The backing layer is impermeable to the drug T.occidentalis salicylic acid TOSA 102. The protective layer is peelable and aids a user in applying the transdermal patch 100 to the skin.

[0037] In one embodiment herein, a series of formulations are developed for T.occidentalis salicylic acid (TOSA) using varying quantities of ingredients to evaluate their physicochemical properties and drug release performance, as shown in Table 1.

[0038] Table 1:
S.No INGREDIENTS FORMULATION CODE
FTP 1 FTP 2 FTP 3 FTP 4 FTP 5 FTP 6 FTP 7
1 Drug T.occidentalis
salicylic acid (TOSA) 150 mg 150 mg 150 mg 150 mg 150 mg 150 mg 150 mg
2 HPMC (Polymer) 400 mg 300 mg 250 mg 167 mg 333mg 350 mg 380 mg
3 PVA (Polymer) 100 mg 200 mg 250 mg 333mg 167mg 150mg 120mg
4 Dibutylphthalatae (Plasticizers) 0.1 mL 0.1 mL 0.1 mL 0.1mL 0.1mL 0.1mL 0.1mL
5 Methanol (Solvent) 10 mL 10 mL 10 mL 10mL 10mL 10mL 10mL
6 DMSO (Penetration enhancer) 0.1 mL 0.1 mL 0.1 mL 0.1mL 0.1mL 0.1mL 0.1mL
7 Distilled water 10 mL 10 mL 10 mL 10mL 10mL 10mL 10mL
8 Glycerol 1 mL 1 mL 1 mL 1mL 1mL 1mL 1mL

[0039] Each formulation, identified as FTP 1 through FTP 7, contained a consistent quantity of TOSA at 150 mg. The formulations are prepared with different ratios of hydroxypropyl methylcellulose (HPMC) 104 and polyvinyl alcohol (PVA) 106, which play crucial roles in the film-forming properties of the transdermal patches. Specifically, FTP 1 included 400 mg of HPMC and 100 mg of PVA, FTP 2 contained 300 mg of HPMC and 200 mg of PVA, FTP 3 had 250 mg of HPMC and 250 mg of PVA, FTP 4 utilized 167 mg of HPMC and 333 mg of PVA, FTP 5 comprised 333 mg of HPMC and 167 mg of PVA, FTP 6 contained 350 mg of HPMC and 150 mg of PVA, and FTP 7 had 380 mg of HPMC and 120 mg of PVA.

[0040] The remaining components in each formulation included 0.1 mL of dibutylphthalate 108 as the plasticizer, which is essential for enhancing the flexibility of the film, and 0.1 mL of dimethyl sulfoxide (DMSO) 112 as the penetration enhancer, which facilitates the absorption of TOSA through the skin. All formulations also used 10 mL of methanol 110 as the solvent to dissolve the polymers, 10 mL of distilled water 114 to further adjust the solution, and 1 mL of glycerol 116 to lubricate the petri dish for casting the final solution.

[0041] In evaluating the physicochemical properties of these formulations, FTP 1 exhibited the most favorable characteristics among all tested samples. The in vitro drug release studies demonstrated that FTP 1 had the fastest cumulative drug release profile compared to the other formulations. This superior performance of FTP 1 is attributed to its optimal balance of HPMC and PVA, as well as the effective plasticization and penetration enhancement achieved with the chosen quantities of dibutylphthalate and DMSO.

[0042] The results confirm that FTP 1 not only possessed the best physical properties but also delivered the drug more efficiently, indicating its potential as the most effective formulation based on both its physicochemical attributes and drug release performance. This demonstrates that careful adjustment of the polymer ratios and the inclusion of plasticizers and enhancers can significantly impact the efficacy of transdermal patches.

[0043] According to another embodiment of the invention, FIG. 2 refers to a flow chart 200 of a method for manufacturing the transdermal patch 100 for Verrucae vulgaris and acne treatment. At step 202, the bioactive polymer 104 and the synthetic polymer 106 are weighed and dissolved in a solvent mixture 110, which includes at least 10 mL of distilled water 114 and 10 mL of methanol, thereby obtaining a polymer solution.

[0044] At step 204, the polymer solution is mixed using a magnetic stirrer at a temperature of at least 45 °C, and the drug T.occidentalis salicylic acid (TOSA) 102 is added to the polymer solution, and mixed thoroughly to obtain a uniform polymer-drug mixture.

[0045] At step 206, the plasticizer 108 and the penetration enhancer 112 are mixed into the polymer-drug mixture and thoroughly mixed to obtain a mixture. At step 208, one drop of a coloring agent (safranin indicator) is added to the mixture to obtain a final casting solution, and a petri dish is lubricated with 1 mL of glycerol 116.

[0046] At step 210, the final casting solution is poured into the lubricated petri dish and allowed to spread evenly over an area of approximately 44.15 cm². At step 212, the petri dish is covered with an inverted funnel, and the solution is allowed to dry at room temperature for a time period of at least 96 hr to form the transdermal patch 100.

[0047] Further, at step 214, the dried film is peeled off and cut into a plurality of square patches measuring 1 cm² each and placed in a desiccator for at least two days for further drying. The plurality of dried patches is wrapped in aluminum foil and stored in self-sealing covers for usage.

[0048] The transdermal patch 100 is replaced with a new patch after a predetermined time period. The transdermal patch 100 can be used in combination with other systemic treatments for Verrucae vulgaris and acne.

[0049] In one embodiment herein, the patch's formulation is optimized to achieve optimal drug release rates, bioavailability, and skin permeation while minimizing adverse effects. In vitro and in vivo evaluations are conducted to assess the patch's physiochemical properties, drug release kinetics, and therapeutic effectiveness against Verrucae vulgaris and acne. The results revealed the potential of the transdermal patch 100 as an effective treatment for dermatological conditions.

[0050] In one example embodiment herein, every formulation exhibited good physiochemical properties such as thickness, weight variation, drug content, uniform weight content, percentage (%) elongation, folding endurance, moisture content, and tensile strength, in addition to the phytochemical evaluation. The transdermal patch 100 for treating warts and acne using natural plant extract medication and modern drug delivery technology is an effective and convenient solution for individuals seeking a targeted and efficient approach to managing their dermatological conditions.

[0051] Numerous advantages of the present disclosure may be apparent from the discussion above. In accordance with the present disclosure, the composition of the transdermal patch 100 for Verrucae vulgaris and acne treatment is disclosed. The proposed invention provides a composition of a transdermal patch 100 that utilizes a combination of natural plant extracts and modern drug delivery technology to enhance therapeutic efficacy and ensure prolonged drug release for Verrucae vulgaris and acne treatment.

[0052] The proposed transdermal patch 100 eliminates the need for frequent application of medication as the transdermal patch 100 provides continuous delivery of medication for an extended period. The transdermal patch 100 reduces the systemic side effects associated with oral medications. The transdermal patch 100 is safe and cost-effective. The transdermal patch 100 enhances patient convenience and adherence. The transdermal patch 100 enhances synergistic effects and targeted action.

[0053] It will readily be apparent that numerous modifications and alterations can be made to the processes described in the foregoing examples without departing from the principles underlying the invention, and all such modifications and alterations are intended to be embraced by this application.
,CLAIMS:CLAIMS:
I / We Claim:
1. A composition of a transdermal patch (100) for verrucae vulgaris and acne treatment, comprising:
0.5 to 1 weight percent of a drug T.occidentalis salicylic acid (TOSA) (102);
1 to 2 weight percent of a bioactive polymer (104);
0.1 to 0.6 weight percent of a synthetic polymer (106);
0.1 to 0.6 weight percent of a plasticizer (108);
40 to 46 weight percent of a solvent (110);
0.1 to 0.6 weight percent of a penetration enhancer (112);
40 to 46 weight percent of distilled water (114); and
3 to 5 weight percent of glycerol (116),
whereby the transdermal patch (100) composition provides a safe and effective solution for the treatment of skin conditions such as verrucae vulgaris and acne.
2. The transdermal patch (100) as claimed in claim 1, wherein the drug T.occidentalis salicylic acid (TOSA) (102) comprises carbohydrates, alkaloids, tannins, saponins, flavonoids, oils, lipids, and glycosides.
3. The transdermal patch (100) as claimed in claim 1, wherein the bioactive polymer (104) is a hydroxypropyl methylcellulose (HPMC) polymer.
4. The transdermal patch (100) as claimed in claim 1, wherein the synthetic polymer (106) is a polyvinyl alcohol (PVA) polymer.
5. The transdermal patch (100) as claimed in claim 1, wherein the plasticizer (108) is a dibutylphthalate.
6. The transdermal patch (100) as claimed in claim 1, wherein the solvent (110) is methanol.
7. The transdermal patch (100) as claimed in claim 1, wherein the penetration enhancer (112) is dimethyl sulfoxide (DMSO).
8. The transdermal patch (100) as claimed in claim 1, wherein the transdermal patch (100) is configured to release the drug T.occidentalis salicylic acid (TOSA) (102) over a predetermined time period of at least 12 hr.
9. The transdermal patch (100) as claimed in claim 1, wherein the transdermal patch (100) comprises a backing layer and a protective layer, wherein
said backing layer is impermeable to the drug T.occidentalis salicylic acid (TOSA) (102); and
said protective layer is peelable and aids a user in applying the transdermal patch (100) to the skin.
10. A method for manufacturing a transdermal patch (100) for verrucae vulgaris and acne treatment, comprising:
weighing a bioactive polymer (104) and a synthetic polymer (106) and dissolving the weighed polymers in a solvent mixture, which includes at least 10 mL of distilled water (114) and 10 mL of methanol, thereby obtaining a polymer solution;
mixing the polymer solution using a magnetic stirrer at a temperature of at least 45°C and adding a drug T.occidentalis salicylic acid (TOSA) (102) to the polymer solution, and mixing thoroughly to obtain a uniform polymer-drug mixture;
mixing a plasticizer (108) and a penetration enhancer (112) into the polymer-drug mixture and mixing thoroughly to obtain a mixture;
adding one drop of a coloring agent to the mixture to obtain a final casting solution, and lubricating a petri dish with 1 mL of glycerol (116);
pouring the final casting solution into the lubricated petri dish, and allowing the final casting solution to spread evenly over an area of approximately 44.15 cm²;
covering the petri dish with an inverted funnel and allowing the solution to dry at room temperature for a time period of at least 96 hr to form the transdermal patch (100); and
peeling off dried film and cutting into a plurality of square patches measuring 1 cm² each and placing the plurality of square patches in a desiccator for at least two days for further drying, and wrapping the plurality of dried patches in aluminum foil and storing in self-sealing covers for usage.